Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.25 | N/A | -197.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.25 | N/A | -197.62% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their pipeline despite the lack of financial guidance.
Management did not provide specific guidance for future performance.
The company is focused on ongoing clinical trials and product development.
The earnings report indicates that Krystal Biotech is struggling to meet expectations, particularly in terms of EPS. The stock's decline of 12.63% reflects investor disappointment, especially given the significant EPS miss. Without revenue figures or guidance, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LYONDELLBASELL INDUS A
Aug 4, 2023